jump to navigation

MBBP’s Life Sciences Vector, Fall 2015 11/30/2015

Posted by Morse Barnes-Brown Pendleton in Client News, Life Sciences, MBBP news, New Resources.
Tags: , , ,
trackback

extU.S. INTRODUCTION TO THE HAGUE SYSTEM

For many years, non-U.S. parties have taken advantage of the Hague System to register their design patents, an important part of strengthening and differentiating your product and brand. On May 13, 2015, the Hague Agreement Implementation of the Patent Law Treaties Implementation Act of 2012 (PLT) went into effect in the U.S. As a result, the U.S. became a member of the Hague System, an international system of registration for design patents (also referred to as “industrial designs” internationally). Now, U.S. applicants wishing to register a design patent in the U.S. and abroad may submit a single application and pay a single fee to register such design patent in all or some of the 63 other Contracting Parties that participate in the Hague Agreement.

Click here to learn more.

4,500 COMPANIES REELING AS EU’S HIGHEST COURT INVALIDATES SAFE HARBOR

On October 6, the Court of Justice of the European Union (“CJEU”) issued a binding judgment invalidating the European Commission Decision (Commission Decision 2000/520, the “Safe Harbor Decision”) that authorized the EU-U.S. Safe Harbor arrangement. For the past fifteen years, this arrangement has been relied upon by many businesses to transfer personal data from the European Union to the United States in compliance with the EU Data Protection Directive (Commission Decision 95/46, the “Directive”). As a result of the CJEU’s judgment, self-certification under the Safe Harbor framework is no longer sufficient to comply with the Directive.

Read more on Page 5.

CONTROLLING THE DEBATE: ANTICIPATORY SELF-DILIGENCE IN BIOTECH BUSINESS DEVELOPMENT

By: Jonathan P. Gertler, Back Bay Life Science Advisors

Business development is the lifeblood of the biotech industry. This article focuses on internal decision making regarding portfolio prioritization, and external anticipatory diligence to maintain optimal control over negotiation dynamics (i.e. “controlling the debate”).

Read more on Page 3.

MBBP ADDS TWO ASSOCIATES

Registered Patent Attorney Erin E. Bryan handles a broad range of intellectual property issues in a number of technical areas. She currently works with a variety of clients, including universities, research organizations and start-ups in the chemical, pharmaceutical and biotechnology areas. She is also proficient in patent prosecution and provides assistance with various phases of IP litigation and counseling.

Corporate Attorney Erik S. Thompson provides services to a range of clients, including emerging businesses and private investment funds, and advises them on mergers and acquisitions, issuances of ISOs and equity options, and regulatory compliance. He also serves as outside counsel to numerous companies, attending Board meetings and advising them on corporate actions.

MBBP ATTORNEYS PRESENT “CONSTRUCTING A SOLID PROVISIONAL PATENT”

In October, Registered Patent Attorneys Sean D. Detweiler and Dr. Stanley F. Chalvire spoke at a program hosted by TechSandBox for its Life Sciences SIG. Joining Sean and Stan were two Life Science CEOs. The panel provided attendees with guidance on how to do a provisional patent, on your own, or on a low budget.

RECENT FINANCINGS IN HEALTHCARE / LIFE SCIENCES

  • NED Biosystems closed a $1.5 million Series B Preferred financing with First Round Capital and angel investors. NED Biosystems provides a adjunct therapy of natural supplements designed to enhance chemotherapy with less toxic side effects.
  • Criscot Inc. closed an $800,000 extension of its Series A-2 Preferred Stock financing. Criscot provides a novel, proprietary applicator for delivery of drug compounds, resulting in more exact dosage without toxicity effects.
  • First Light Biosciences Inc. closed a $3.0 million Series B Preferred Stock financing. First Light Biosciences provides a patented instrument for early and swift detection of pathogens during the hospital admissions process, reducing the risk of hospital-acquired infections.

SELVITA ESTABLISHES FIRST U.S. OPERATIONS  IN GREATER BOSTON AREA

MBBP client, Selvita, recently announced an expansion into the Boston-area biotechnology and pharmaceutical market, as they open a fully-owned US subsidiary, Selvita Inc., headquartered in Cambridge, Massachusetts. Selvita is a leading global drug discovery company and the largest drug discovery company in Central and Eastern Europe. The new office, located at 485 Massachusetts Ave., will focus largely on expanding the company’s existing clients for its drug discovery services, as well as exploring and developing partnering opportunities.

Read more.

HENKE-SASS, WOLF A SO-CALLED “HIDDEN CHAMPION”

Every day, people all over the world use products and solutions produced by Henke-Sass, Wolf – often without even realizing it, as most of our products have the brand and label of our customers and not ours. As a medium-sized international company, and a technological leader in the medical endoscopy sector, we are sometimes considered a “hidden champion” – but certainly not “hidden” from our longstanding business partners and loyal customers.

Read more.

Comments»

No comments yet — be the first.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: